Clinical and Molecular Hepatology (대한간학회지)

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

Type and cause of liver disease in Korea: single-center experience, 2005-2010

  • Lee, Sang-Soo (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Byoun, Young-Sang (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Jeong, Sook-Hyang (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Yeo-Myung (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Gil, Ho (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Min, Bo-Young (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Seong, Mun-Hyuk (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Jang, Eun-Sun (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Jin-Wook (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
  • Published : 2012.09.25
⟨ Previous Next ⟩

Abstract

Background/Aims: The aim of this study was to describe the types and causes of liver disease in patients from a single community hospital in Korea between April 2005 and May 2010. Methods: A cohort of patients who visited the liver clinic of the hospital during the aforementioned time period were consecutively enrolled (n =6,307). Consistent diagnostic criteria for each liver disease were set by a single, experienced hepatologist, and the diagnosis of all of the enrolled patients was confirmed by retrospective review of their medical records. Results: Among the 6,307 patients, 528 (8.4%) were classified as acute hepatitis, 3,957 (62.7%) as chronic hepatitis, 767 (12.2%) as liver cirrhosis, 509 (8.1%) as primary liver cancer, and 546 (8.7%) as a benign liver mass or other diseases. The etiologies in the acute hepatitis group in decreasing order of prevalence were hepatitis A (44.3%), toxic hepatitis (32.4%), other hepatitis viruses (13.8%), and cryptogenic hepatitis (9.1%). In the chronic hepatitis group, 51.2% of cases were attributed to viral hepatitis, 33.3% to nonalcoholic fatty liver disease, and 13.0% to alcoholic liver disease (ALD). Of the cirrhoses, 73.4% were attributable to viral causes and 18.1% to alcohol. Of the hepatocellular carcinoma cases, 86.6% were attributed to viral hepatitis and 11.6% to ALD. Among the benign tumors, hemangioma comprised 52.2% and cystic liver disease comprised 33.7%. Conclusions: Knowledge of the current status of the type and cause of liver disease in Korea may be valuable as a basis for evaluating changing trends in liver disease in that country.

Keywords

References

  1. Kochanek KD, Xu J, Murphy SL, Miniño AM, Kung H-C. National vital statistics report. Deaths: Preliminary Data for 2009. Centers for Disease Control and Prevention. 2011;59:1-51.
  2. Korea National Statical Office. Annual Report on the Cause of Death Statics 2010. 2011.
  3. Lee S, Chung W, Hyun KR. Socioeconomic costs of liver disease in Korea. Korean J Hepatol 2011;17:274-291. https://doi.org/10.3350/kjhep.2011.17.4.274
  4. Korean Liver Cancer Study Group and National Cancer Center, Korea. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009;15:391-423. https://doi.org/10.3350/kjhep.2009.15.3.391
  5. Kang HM, Jeong SH, Kim JW, Lee D, Choi CK, Park YS, et al. Recent etiology and clinical features of acute viral hepatitis in a single center of Korea. Korean J Hepatol 2007;13:495-502. https://doi.org/10.3350/kjhep.2007.13.4.495
  6. Korea Center for Disease Control and Prevention (CDC). Sentinel Surveillance: Viral hepatitis statics. CDC web site. , Acceessed on May 1st, 2012.
  7. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008;48(Suppl 1):S104- S112.
  8. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004;350:1118-1129. https://doi.org/10.1056/NEJMra031087
  9. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003;362:2095-2100. https://doi.org/10.1016/S0140-6736(03)15109-4
  10. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21:138-143 https://doi.org/10.1111/j.1440-1746.2005.04086.x
  11. Korea Centers for Disease Control and Prevention (CDC). Korea Health Statistics 2010: Korea National Health and Nutrition Examination Survey (KNHANES V-1). CDC web site. , Acceessed 2010.
  12. Suh DJ, Jeong SH. Current status of hepatitis C virus infection in Korea. Intervirology 2006;49:70-75. https://doi.org/10.1159/000087266

Cited by

  1. HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data vol.19, pp.4, 2012, https://doi.org/10.3350/cmh.2013.19.4.409
  2. Clinical Features and Risk Factors for Severe Complications among Patients with Acute Hepatitis A Virus Infection in The Jeonbuk Province of Korea vol.63, pp.1, 2012, https://doi.org/10.4166/kjg.2014.63.1.25
  3. The refit model for end-stage liver disease-Na is not a better predictor of mortality than the refit model for end-stage liver disease in patients with cirrhosis and ascites vol.20, pp.1, 2012, https://doi.org/10.3350/cmh.2014.20.1.47
  4. Epigenetic Mechanisms Underlying the Link between Non-Alcoholic Fatty Liver Diseases and Nutrition vol.6, pp.8, 2012, https://doi.org/10.3390/nu6083303
  5. Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B vol.20, pp.3, 2012, https://doi.org/10.3350/cmh.2014.20.3.274
  6. Health Screening among HBV Carriers in the Korean National Health and Nutrition Examination Survey V (KNHANES V) vol.16, pp.9, 2015, https://doi.org/10.7314/apjcp.2015.16.9.3653
  7. Factors associated with significant liver fibrosis assessed using transient elastography in general population vol.21, pp.4, 2012, https://doi.org/10.3748/wjg.v21.i4.1158
  8. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors vol.36, pp.4, 2012, https://doi.org/10.1097/mnm.0000000000000254
  9. Epidemiology of Hepatitis C Virus Infection in Korea vol.88, pp.6, 2012, https://doi.org/10.3904/kjm.2015.88.6.630
  10. Prospective cohort study on the outcomes of hepatitis C virus‐related cirrhosis in South Korea vol.30, pp.8, 2012, https://doi.org/10.1111/jgh.12950
  11. New direct-acting antivirals for the treatment of chronic hepatitis C vol.58, pp.12, 2012, https://doi.org/10.5124/jkma.2015.58.12.1154
  12. Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial vol.35, pp.6, 2012, https://doi.org/10.1080/07315724.2015.1031355
  13. The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy vol.22, pp.2, 2012, https://doi.org/10.3350/cmh.2015.0053
  14. Illness Experience of Patients with Chronic Hepatitis C Participating in Clinical Trials vol.7, pp.6, 2012, https://doi.org/10.1016/j.phrp.2016.11.001
  15. Clinical features of hepatitis B and C virus infections, with high α-fetoprotein levels but not hepatocellular carcinoma vol.96, pp.2, 2012, https://doi.org/10.1097/md.0000000000005844
  16. Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea vol.12, pp.8, 2017, https://doi.org/10.1371/journal.pone.0182391
  17. Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea vol.24, pp.1, 2012, https://doi.org/10.3350/cmh.2017.0066
  18. Epidemiology of alcoholic liver disease in Korea vol.24, pp.2, 2012, https://doi.org/10.3350/cmh.2017.0079
  19. Seropositivity of Hepatitis C Virus among Persons affected Leprosy in Korea vol.51, pp.1, 2012, https://doi.org/10.33161/klb.2018.51.1.13
  20. Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea vol.124, pp.13, 2012, https://doi.org/10.1002/cncr.31406
  21. Nuclear factor erythroid 2-related factor 2 활성화를 통한 해간전(解肝煎)의 간세포 보호 효능 및 분자기전을 활용한 해간전(解肝煎) 구성 약물의 최적화 연구 vol.26, pp.3, 2012, https://doi.org/10.14374/hfs.2018.26.3.207
  22. Recognition criteria for occupational cancers in relation to hepatitis B virus and hepatitis C virus in Korea vol.30, pp.1, 2012, https://doi.org/10.1186/s40557-018-0217-0
  23. Cost-effectiveness of scaling up of hepatitis C screening and treatment: a modelling study in South Korea vol.4, pp.3, 2012, https://doi.org/10.1136/bmjgh-2019-001441
  24. The roles of transmembrane 6 superfamily member 2 rs58542926 polymorphism in chronic liver disease: A meta‐analysis of 24,147 subjects vol.7, pp.8, 2012, https://doi.org/10.1002/mgg3.824
  25. Harmful algal blooms and liver diseases: focusing on the areas near the four major rivers in South Korea vol.37, pp.4, 2012, https://doi.org/10.1080/10590501.2019.1674600
  26. Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associat vol.91, pp.12, 2012, https://doi.org/10.1002/jmv.25575
  27. Analysis of HCV RNA Genotypes and Quantitative Values of Korean HCV NAT Reactive Blood Donors vol.30, pp.3, 2012, https://doi.org/10.17945/kjbt.2019.30.3.205
  28. Bile duct ligation of C57BL/6 mice as a model of hepatic encephalopathy vol.15, pp.1, 2012, https://doi.org/10.17085/apm.2020.15.1.19
  29. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission vol.5, pp.2, 2012, https://doi.org/10.1016/s2468-1253(19)30342-5
  30. Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose vol.14, pp.6, 2012, https://doi.org/10.5009/gnl19260
  31. Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study vol.36, pp.suppl1, 2012, https://doi.org/10.3904/kjim.2019.357